Neutropenia febril de bajo riesgo en pacientes oncológicos

Abstract

Background: Infections constitute the major cause of morbimortality in pediatric patients treated with chemotherapy. The PINDA Infectology Committee (National Program of Antineoplasic Drugs) validated a model to predict the risk of invasive bacterial infection (IBI) in oncological patients with febrile neutropenia (FN), in order to differentiate episodes of low risk (LRFN) versus high risk (HRFN) of IBI. Objective: Characterize LRFN episodes in patients treated at the Oncology Unit of Hospital Roberto del Río, between 2003-2006. Method: Retrospective study of clinical charts of patients with cancer and LRFN in the period of time selected. Results: 185 patients with 202 FN episodes registered, where 47 correspond to LRFN (23%). 8.5% of LRFN episodes had an unfavourable outcome (not statistically significant). In these patients, cultures were negative and required more days of hospitalization. No patients were readmitted and had no infection associated mortality. Conclusion: The selective management of patients with LRFN following the current criteria is safe and effective.